HOTH
Hoth Therapeutics, Inc. NASDAQ Listed Feb 15, 2019$0.88
-12.67%
vs $1.01
Mkt Cap $11.7M
52w Low $0.49
20.0% of range
52w High $2.45
50d MA $0.80
200d MA $1.11
P/E (TTM)
—
EV/EBITDA
—
P/B
2.0x
Debt/Equity
0.0x
ROE
-202.7%
P/FCF
-1.4x
RSI (14)
19.80
ATR (14)
$0.23
Beta
0.60
50d MA
$0.80
200d MA
$1.11
Avg Volume
19.7M
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
1 Rockefeller Plaza · New York City, NY 10020 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27, 2026 | AMC | -0.10 | -0.16 | -55.2% | 0.81 | -1.7% | -4.4% | +9.1% | -34.9% | +2.6% | +3.0% | — |
| Nov 12, 2025 | AMC | -0.30 | -0.30 | +0.0% | 1.28 | -3.9% | -7.8% | +0.8% | -1.7% | +0.9% | -2.5% | — |
| Aug 12, 2025 | AMC | -0.27 | -0.17 | +37.0% | 1.27 | +3.9% | +2.4% | -0.8% | -0.8% | +0.8% | -1.6% | — |
| May 12, 2025 | AMC | -0.34 | -0.27 | +20.6% | 0.93 | -2.2% | -3.2% | -3.2% | -2.2% | +1.1% | -1.2% | — |
| Mar 28, 2025 | AMC | -0.39 | -0.32 | +17.9% | 1.03 | -1.0% | -2.9% | -2.5% | +0.4% | -4.7% | -10.0% | — |
| Nov 12, 2024 | AMC | -0.30 | -0.31 | -3.3% | 0.90 | -5.4% | -2.9% | -3.2% | -3.2% | -3.3% | +3.4% | — |
| Aug 9, 2024 | AMC | -0.39 | -0.24 | +38.5% | 0.61 | -0.0% | +2.3% | -2.8% | -0.2% | +2.0% | +14.1% | — |
| May 14, 2024 | AMC | -0.43 | -0.46 | -7.0% | 1.18 | -0.8% | -1.7% | +2.6% | -0.8% | +1.7% | -1.7% | — |
| Mar 28, 2024 | AMC | -0.51 | -0.31 | +39.2% | 1.52 | -2.6% | -6.6% | -3.5% | +3.6% | +0.7% | -2.1% | — |
| Nov 13, 2023 | AMC | -0.72 | -0.60 | +16.7% | 1.13 | +6.2% | -0.9% | -8.0% | +1.0% | +4.0% | -1.1% | — |
| Aug 11, 2023 | AMC | -1.16 | -0.57 | +50.9% | 2.57 | -6.6% | -0.4% | +0.0% | -1.2% | -4.3% | -0.8% | — |
| May 15, 2023 | AMC | -0.86 | -0.88 | -2.3% | 1.60 | +1.2% | +0.6% | -3.7% | +1.3% | +2.5% | -1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | D. Boral Capital | Maintains | Buy → Buy | — | $0.89 | $0.90 | +1.5% | +1.4% | -6.7% | -4.0% | -4.4% | +9.1% |
| Mar 4 | D. Boral Capital | Maintains | Buy → Buy | — | $1.00 | $0.99 | -0.7% | +3.3% | -1.9% | -1.7% | -0.3% | +1.0% |
| Dec 4 | D. Boral Capital | Maintains | Buy → Buy | — | $1.20 | $1.20 | +0.0% | -0.8% | +0.8% | -3.3% | +2.6% | +1.7% |
| Nov 17 | D. Boral Capital | Maintains | Buy → Buy | — | $1.19 | $1.20 | +0.8% | -1.7% | +0.9% | -2.5% | -10.4% | +5.8% |
| Aug 18 | D. Boral Capital | Maintains | Buy → Buy | — | $1.28 | $1.28 | +0.0% | +0.8% | -1.6% | -1.6% | +3.2% | +0.8% |
| Jul 30 | D. Boral Capital | Maintains | Buy → Buy | — | $1.30 | $1.28 | -1.5% | +3.8% | -1.5% | -1.5% | +6.9% | -1.4% |
| Jul 23 | D. Boral Capital | Maintains | Buy → Buy | — | $1.32 | $1.31 | -0.8% | +3.0% | -4.4% | -1.5% | +2.3% | -0.8% |
| Jun 26 | D. Boral Capital | Maintains | Buy → Buy | — | $1.19 | $1.19 | +0.0% | -1.7% | -3.4% | +3.5% | +4.3% | -1.6% |
| Jun 12 | D. Boral Capital | Maintains | Buy → Buy | — | $1.32 | $1.40 | +6.1% | +7.6% | -8.5% | +0.8% | -0.8% | +3.1% |
| Apr 15 | D. Boral Capital | Maintains | Buy → Buy | — | $0.83 | $0.84 | +1.4% | -2.3% | -4.0% | +1.8% | -2.0% | +3.7% |
| Apr 3 | D. Boral Capital | Maintains | Buy → Buy | — | $0.98 | $0.94 | -4.4% | -4.7% | -10.0% | -6.0% | -12.3% | +16.1% |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $1.03 | $1.02 | -1.0% | -2.9% | -2.5% | +0.4% | -4.7% | -10.0% |
| Mar 10 | D. Boral Capital | Maintains | Buy → Buy | — | $1.09 | $1.10 | +0.9% | +0.9% | +2.7% | -1.8% | -1.8% | +1.8% |
| Mar 6 | D. Boral Capital | Maintains | Buy → Buy | — | $1.14 | $1.13 | -0.9% | -7.9% | +3.8% | +0.9% | +2.7% | -1.8% |
| Mar 4 | D. Boral Capital | Maintains | Buy → Buy | — | $0.87 | $0.91 | +4.7% | +42.5% | -8.1% | -7.9% | +3.8% | +0.9% |
| Feb 11 | D. Boral Capital | Maintains | Buy → Buy | — | $1.08 | $1.04 | -3.7% | -5.6% | +5.9% | -0.9% | +5.6% | -0.9% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.36 | $1.41 | +3.7% | +8.1% | -7.5% | -10.3% | +5.7% | -3.9% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.42 | $1.40 | -1.4% | -4.2% | +8.1% | -7.5% | -10.3% | +5.7% |
| Jan 7 | D. Boral Capital | Maintains | Buy → Buy | — | $0.82 | $1.67 | +103.8% | +178.2% | -16.7% | +0.0% | -0.5% | -18.0% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.86 | $0.88 | +2.2% | +3.5% | +0.8% | -1.8% | +1.8% | +2.3% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.62 | $0.63 | +2.1% | +14.1% | +7.2% | -9.6% | +2.7% | +3.6% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.81 | $0.90 | +11.1% | +3.0% | -6.6% | -14.1% | +2.6% | +0.4% |
| Jul 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.82 | $0.83 | +0.9% | +2.1% | +15.8% | +10.1% | -24.3% | +3.0% |
| Apr 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.43 | $1.45 | +1.4% | -2.1% | -4.3% | -4.5% | -1.6% | +0.8% |
| Apr 2 | EF Hutton | Maintains | Buy → Buy | — | $1.42 | $1.47 | +3.5% | -3.5% | +3.6% | +0.7% | -2.1% | -4.3% |
| Sep 14 | EF Hutton | Maintains | Buy → Buy | — | $1.92 | $1.80 | -6.2% | -7.8% | +4.0% | -7.1% | -2.9% | +5.4% |
| Jun 20 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $3.01 | $2.86 | -5.0% | -4.7% | +3.8% | +1.0% | +2.7% | -0.6% |
| Apr 27 | EF Hutton | Maintains | Buy → Buy | — | $1.74 | $1.66 | -4.6% | -5.7% | +5.5% | +0.6% | +0.6% | -2.9% |
| Apr 10 | Benchmark | Maintains | Speculative Buy → Buy | — | $2.01 | $2.01 | +0.0% | +1.0% | +2.5% | +1.9% | +1.4% | -4.7% |
| Apr 3 | EF Hutton | Maintains | Buy → Buy | — | $2.06 | $2.15 | +4.4% | +1.0% | +0.0% | -4.3% | +1.0% | +1.0% |
| Dec 30 | EF Hutton | Maintains | Buy → Buy | — | $10.72 | $7.61 | -29.0% | -27.2% | -15.9% | -0.5% | -9.6% | +6.6% |
| Aug 23 | EF Hutton | Maintains | Buy → Buy | — | $10.53 | $10.50 | -0.3% | -2.7% | +6.1% | +0.5% | -2.3% | +5.3% |
| Mar 31 | EF Hutton | Maintains | Buy → Buy | — | $17.48 | $17.75 | +1.5% | -1.0% | -0.3% | +3.2% | -3.9% | -3.5% |
| Oct 15 | Benchmark | Maintains | Speculative Buy → Buy | — | $106.00 | $112.50 | +6.1% | +1.7% | -3.0% | -4.5% | -1.8% | +10.2% |
| May 20 | Laidlaw & Co. | Maintains | Buy → Buy | — | $134.25 | $137.25 | +2.2% | -6.0% | +5.0% | -2.5% | -2.3% | +3.6% |
No insider trades available.
8-K · 8.01
!! High
Hoth Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 3
8-K · 8.01
!! High
Hoth Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 3
8-K · 8.01
!! High
Hoth Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 2
8-K · 8.01
!! High
Hoth Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 28
8-K · 8.01
!! High
Hoth Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Hoth Therapeutics completed a name and ticker symbol change effective May 27, 2026, signaling a potential strategic repositioning or rebranding that investors should monitor for operational implications.
May 27
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Hoth Therapeutics filed a routine 8-K with minimal disclosure, suggesting either a technical filing requirement or delayed announcement that may indicate weak corporate governance or communication, warranting investor caution.
Apr 16
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
HOTH diluted shareholders by issuing equity to raise minimal capital ($2), signaling financial desperation and likely indicating severe liquidity concerns that could threaten operations.
Apr 2
Valuation
Market Cap
$11.7M
Enterprise Value
$7.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.04x
P/B
1.98x
P/S
—
P/FCF
-1.42x
EV/EBITDA
—
Shares Out
13.8M
Financials (TTM)
Revenue
$0
Net Income
-$11.7M
EBITDA
-$11.7M
Free Cash Flow
-$9.8M
Op Cash Flow
-$9.8M
EPS Basic
$-0.90
EPS Diluted
$-0.81
EPS Forward
$-0.59
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$7.6M
Total Liab.
$1.5M
Total Equity
$6.2M
Cash
$6.2M
LT Debt
$0
Book Value/Sh
$0.45
Debt/Equity
0.00x
Current Ratio
4.72
Quick Ratio
4.72
Returns & Growth
ROE
-202.7%
ROA
-164.0%
ROIC
-180.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
+29.7%
Price Returns
2W
+106.1%
1M
+127.9%
3M
+68.3%
6M
+40.5%
12M
+104.7%
Technicals
52W High
$2.45
52W Low
$0.49
50d MA
$0.80
200d MA
$1.11
RSI (14)
19.80
ATR (14)
$0.23
Beta
0.60
Avg Volume
19.7M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 1:51pm
· Source: financialmodelingprep.com